Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 381-392 , November 2007

Metabolic complications associated with use of thiazide diuretics

  • Biff F. Palmer, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Biff F. Palmer, MD, Department of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75390. Tel: 214-648-7848; fax: 214-648-2071.
    • ,
  • Amir Said Alizadeh Naderi, MD

Received 3 July 2007 ,Accepted 24 July 2007.

References 

  1. Stanton BA. Cellular actions of thiazides in the distal tubule. J Am Soc Nephrol. 1990;1:832–836
  2. Boer WH, Koomans HA, Dorhout Mees EJ. Acute effects of thiazides, with and without carbonic anhydrase inhibiting activity, on lithium and free water clearance in man. Clin Sci. 1989;76:539–545
  3. Guntupalli J, Onuigbo M, Wall S, Alpern RJ, DuBose TD. Adaptation to low–K+ media increases H(+)–K(+)–ATPase but not H(+)–ATPase-mediated pHi recovery in OMCD1 cells. Am J Physiol. 1997;273:C558–C571
  4. Hebert SC, Desir G, Giebisch G, Wang W. Molecular diversity and regulation of renal potassium channels. Physiol Rev. 2005;85:319–371
  5. Giebisch G, Krapf R, Wagner C. Renal and extrarenal regulation of potassium. Kidney Int. 2007;72:397–410
  6. Komlosi P, Fintha A, Bell PD. Current mechanisms of macula densa cell signalling. Acta Physiol Scand. 2004;181:463–469
  7. Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141:1015–1019
  8. van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin, and aldosterone in essential hypertension. Acta Med Scand. 1978;204:151–157
  9. Kassirer JP, Harrington JT. Diuretics and potassium metabolism: a reassessment of the need, effectiveness, and safety of potassium therapy. Kidney Int. 1977;11:505–515
  10. Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation. 1986;73:114–123
  11. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial (Multiple Risk Factor Intervention Trial Research Group). Am J Cardiol. 1985;55:1–15
  12. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852–1857
  13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264
  14. Medical Research Council trial of treatment of hypertension in older adults: principal results (MRC Working Party). BMJ. 1992;304:405–412
  15. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–1285
  16. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277:739–745
  17. Kaplan NM, Carnegie A, Raskin P, Heller JA, Simmons M. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med. 1985;312:746–749
  18. Smith NL, Lemaitre RN, Heckbert SR, Kaplan RC, Tirschwell DL, Longstreth WT, et al. Serum potassium and stroke risk among treated hypertensive adults. Am J Hypertens. 2003;16:806–813
  19. Palmer BF. Managing hyperkalemia caused by inhibitors of the rennin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585–592
  20. Palmer BF, Alpern RJ. Metabolic alkalosis. J Am Soc Nephrol. 1997;8:1462–1469
  21. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37:1694–1702
  22. Kim GH, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, et al. Anti-diuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with up-regulation of aquaporin-2, Na+–Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol. 2004;15:2836–2843
  23. Byatt CM, Millard PH, Levin GE. Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. J R Soc Med. 1990;83:704–708
  24. Gross P, Palm C. Thiazides: do they kill?. Nephrol Dial Transplant. 2005;20:2299–2301
  25. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol. 2006;61:87–95
  26. Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37:149–155
  27. Palmer BF. Renal complications associated with use of non-steroidal anti-inflammatory agents. J Investig Med. 1995;43:516–533
  28. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol. 2007;19:151–157
  29. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens. 2003;12:511–516
  30. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002;417:447–452
  31. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319:10–24
  32. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004;308:1021–1029
  33. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18:430–439
  34. Reyes A. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17:397–414
  35. Cauley J, Cummings S, Seeley D, Black D, Browner W, Kuller L, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls (The study of osteoporotic fractures research group). Ann Int Med. 1993;118:666–673
  36. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. New Engl J Med. 1990;322:286–290
  37. Friedman PA. Codependence of renal calcium and sodium transport. Annu Rev Physiol. 1998;60:179–197
  38. Hoenderop J, Nilius B, Bindels R. Epithelial calcium channels: from identification to function and regulation. Pflugers Arch. 2003;446:304–308
  39. Nijenhuis T, Hoenderop J, Bindels R. TRPV5 and TRPV6 in Ca (2+) (re)absorption: regulating Ca (2+) entry at the gate. Pflugers Arch. 2005;451:181–192
  40. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, et al. Thiazide treatment of rates provokes apoptosis in distal tubule cells. Kidney Int. 1996;50:1180–1190
  41. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115:1651–1658
  42. Efrati E, Arsentiev–Rozenfeld J, Zelikovic I. The human paracellin-1 gene (hPCLN-1): renal epithelial cell-specific expression and regulation. Am J Physiol Renal Physiol. 2005;288:F272–F283
  43. Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int. 1995;47:1419–1425
  44. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350–357
  45. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39:167–174
  46. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes Care. 1991;14(Suppl 4):S33–S38
  47. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens. 2004;22:1845–1847
  48. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777–1781
  49. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10
  50. Zillich A, Garg J, Basu S, Bakris G, Carter B. Thiazide diuretics, potassium, and the development of diabetes: a quatitative review. Hypertension. 2006;48:219–224
  51. Cutler J. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key. Hypertension. 2006;48:198–200
  52. Koster JC, Remedi MS, Masia R, Patton B, Tong A, Nichols CG. Expression of ATP-insensitive KATP channels in pancreatic beta cells underlies a spectrum of diabetic phenotypes. Diabetes. 2006;55:2957–2964
  53. Barzilay J, Cutler J, Davis B. Antihypertensive medications and risk of diabetes mellitus. Curr Opin Nephrol Hypertens. 2007;16:256–260
  54. van Brummelen P, Gevers Leuven JA, van Gent CM. Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. Curr Med Res Opin. 1979;6:24–29
  55. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia?. Am Heart J. 2000;139:174–183
  56. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta analysis. JAMA. 2003;289:2534–2544

 Conflict of interest: none.

PII: S1933-1711(07)00164-7

doi: 10.1016/j.jash.2007.07.004

Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 381-392 , November 2007

Article Tools

* Image Usage & Resolution